Document Type : Commentary

Authors

1 Bevelacqua Resources, Richland, WA, United States

2 Pediatric Infectious Ward, Yasuj University of Medical Sciences, Yasuj, Iran

3 School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

4 Department of Immunology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran

5 Department of Radiology, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran

6 Vice-chancellery for Research, Shiraz University of Medical Sciences, Shiraz, Iran

7 Faculty of Medicine, Szeged University, Szeged, Hungary

10.31661/jbpe.v0i0.2206-1514

Abstract

During the early days of the COVID-19 pandemic, low dose radiation therapy (LDRT) was proposed as a potentially effective treatment method. To minimize potential toxicity, the initial treatment approach involved a few mGy of adapting radiation followed by a single 250 mGy whole lung challenging dose. However, antiviral drugs were also introduced as a promising treatment option, which were thought to have the potential to revolutionize the management of the crisis. Despite early warnings, many physicians did not fully consider the key point that, in contrast with LDRT, antiviral drug treatments can result in strong selective pressure on the virus. This can lead to the emergence of new SARS-CoV-2 variants, a phenomenon that can have serious global consequences. After more than two years, the truth has been revealed: the WHO Guideline Development Group has advised against the use of remdesivir, a widely used antiviral medication, for COVID-19. Meanwhile, a growing body of evidence suggests that LDRT can be a promising, low-risk approach for avoiding or delaying invasive respiratory support in COVID-19 patients. Although there is substantial supporting documentation, more high-quality, controlled, and randomized double-blind clinical trials are needed to further investigate the efficacy and potential therapeutic mechanisms of LDRT for COVID-19.

Highlights

Joseph John Bevelacqua (PubMed)

Masoud Haghani (Google Scholar)

Keywords

  1. Ghadimi-Moghadam A, Haghani M, Bevelacqua JJ, Jafarzadeh A, Kaveh-Ahangar A, Mortazavi SMJ, et al. COVID-19 Tragic Pandemic: Concerns over Unintentional “Directed Accelerated Evolution” of Novel Coronavirus (SARS-CoV-2) and Introducing a Modified Treatment Method for ARDS. J Biomed Phys Eng. 2020;10(2):241-6. doi: 10.31661/jbpe.v0i0.2003-1085. PubMed PMID: 32337192. PubMed PMCID: PMC7166223.
  2. Mortazavi SMJ, Kefayat A, Cai J. Point/Counterpoint. Low-dose radiation as a treatment for COVID-19 pneumonia: A threat or real opportunity? Med Phys. 2020;47(9):3773-6. doi: 10.1002/mp.14367. PubMed PMID: 32619276. PubMed PMCID: PMC7362107.
  3. WHO Guideline Development Group advises against use of remdesivir for covid-19. BMJ; 2020. Available from: https://www.bmj.com/company/newsroom/who-guideline-development-group-advises-against-use-of-remdesivir-for-covid-19/.
  4. Rodríguez-Tomàs E, Acosta JC, Torres-Royo L, De Febrer G, Baiges-Gaya G, Castañé H, et al. Effect of low-dose radiotherapy on the circulating levels of paraoxonase-1-related variables and markers of inflammation in patients with COVID-19 pneumonia. 2022;11(6):1184. doi: 10.3390/antiox11061184. PubMed PMID: 35740079. PubMed PMCID: PMC9220239.
  5. Piras A, Venuti V, D’Aviero A, Cusumano D, Pergolizzi S, Daidone A, Boldrini L. Covid-19 and radiotherapy: a systematic review after 2 years of pandemic. Clin Transl Imaging. 2022;10(6):611-30. doi: 10.1007/s40336-022-00513-9. PubMed PMID: 35910079. PubMed PMCID: PMC9308500.
  6. Jafarzadeh A, Jafarzadeh S, Pardehshenas M, Nemati M, Mortazavi SMJ. Development and exacerbation of autoimmune hemolytic anemia following COVID-19 vaccination: A systematic review. Int J Lab Hematol. 2023;45(2):145-55. doi: 10.1111/ijlh.13978. PubMed PMID: 36208056. PubMed PMCID: PMC9874780.
  7. Ghadimi Moghadam A, Masoumi SJ, Nouri M, Paimard A, Ghadimi Moghadam A, Ghadimi Moghadam F, Firoozi D. The Effect of Nutrients Intake with an Emphasis on Immune-Boostings in Patients with COVID-19. Int J Nutr Sci. 2022;7(1):34-40. doi: 10.30476/IJNS.2022.94174.1170.
  8. Mortazavi SAR, Ghadimi-Moghadam A, Haghani M, Kaveh-Ahangar A, Mortazavi SMJ, Jafarzadeh A. Health care policy makers’ response to COVID-19 pandemic; Pros and cons of “flattening the curve” from the “selective pressure” point of view: a review. Iran J Public Health. 2020;49(6):1053-9.
  9. Mortazavi SAR, Bevelacqua JJ, Welsh JS, Masoumi SJ, Bahaaddini Beigy Zarandi BF, Ghadimi-Moghadam A, et al. The Paradox of COVID-19 in Sub-Saharan Africa: Why it is More Unethical not to Investigate Low Dose Radiotherapy for COVID-19. J Biomed Phys Eng. 2022;12(5):539-42. doi: 10.31661/jbpe.v0i0.2110-1411. PubMed PMID: 36313404. PubMed PMCID: PMC9589076.
  10. Bevelacqua JJ, Mortazavi SA, Mortazavi SM. Re: Low-dose radiation therapy for COVID-19 pneumonia: is there any supportive evidence? Int J Radiat Biol. 2020;96(10):1236-7. doi: 10.1080/09553002.2020.1797213. PubMed PMID: 32673140.
  11. Ghaderian M, Kiani M, Shahbazi-Gahrouei S, Shahbazi-Gahrouei D, Ghadimi Moghadam A, Haghani M. COVID-19 and MERS: Are their Chest X-ray and Computed Tomography Scanning Signs Related? J Med Signals Sens. 2021;12(1):1-7. doi: 10.4103/jmss.JMSS_84_20. PubMed PMID: 35265460. PubMed PMCID: PMC8804588.
  12. Firoozi D, Haqqani M, Javadan Sirat S, Paymard A, Ghadimi Moghadam AK. Investigation of the prevalence of underlying diseases in Covid-19 patients in Yasuj. Armaghane Danesh. 2021;25:937-44.
  13. Mortazavi SAR, Bevelacqua JJ, Rafiepour P, Ghadimi-Moghadam A, Saraei P, Jooyan N, et al. Revisiting the Paradox of Smoking: Radioactivity in Tobacco Smoke or Suppressing the SARS-CoV-2 Receptor, Angiotensin-Converting Enzyme 2, via Aryl-Hydrocarbon Receptor Signal? Dose-Response. 2022;20(1):1-5. doi: 10.1177/15593258221075111. PubMed PMID: 35392263. PubMed PMCID: PMC8980405.
  14. Mortazavi SAR, Mortazavi SMJ, Sihver L. Selective Pressure-Free Treatments for COVID-19. Radiation. 2020;1(1):18-32. doi:10.3390/radiation1010003.
  15. Mortazavi SM, Shams SF, Mohammadi S, Mortazavi SA, Sihver L. Low-dose radiation therapy for COVID-19: A systematic review. 2021;1(3):234-49. doi: 10.3390/radiation1030020.
  16. Mortazavi SM, Zarandi BB, Jafarzadeh A, Mortazavi SA, Sihver L. COVID-19 Update: The Golden Time Window for Pharmacological Treatments and Low Dose Radiation Therapy. Radiation. 2022;2(3):268-72. doi: 10.3390/radiation2030020.
  17. Yarbakhsh R, Mortazavi SA, Mortazavi SM, Parsaei H, Rad D. Artificial intelligence effectively predicts the COVID-19 death rate in different UK cities. Journal of Intelligent & Fuzzy Systems. 2022;43(2):1853-7. doi: 10.3233/JIFS-219286.
  18. Masoumi SJ, Haghani M, Mokkaram P, Firoozi D, Mortazavi SAR, Moradi Ardekani F, et al. Family History of Alzheimer's Disease Increases the Risk of COVID-19 Positivity: A SUMS Employees Cohort-based Study. J Biomed Phys Eng. 2023;13(4):363-6. doi: 10.31661/jbpe.v0i0.2104-1318. PubMed PMID: 37609510. PubMed PMCID: PMC10440408.
  19. Mehdizadeh AR, Bevelacqua JJ, Mortazavi SAR, Welsh JS, Mortazavi SMJ. How Antivirals Might be Linked to the Emergence of New Variants of SARS-CoV-2. J Biomed Phys Eng. 2021;11(2):123-4. doi: 10.31661/jbpe.v0i0.2101-1275. PubMed PMID: 33937119. PubMed PMCID: PMC8064135.
  20. Mortazavi SA, Jooyan N, Baha’addini Baigy Zarandi BF, Jooyan N, Faraz M, Mortazavi SMJ. Coming Out of Nowhere: The Paradox of the Birth of Omicron. J Biomed Phys Eng. 2022;12(4):325-6. doi: 10.31661/jbpe.v0i0.2202-1456. PubMed PMID: 36059290. PubMed PMCID: PMC9395623.
  21. Mehdizadeh AR, Bevelacqua JJ, Welsh JS, Mortazavi SAR, Haghshenas L, Mortazavi SMJ. Why Are Physicists Involved in the Studies on the Origin of SARS-CoV-2? J Biomed Phys Eng. 2021;11(4):413-4. doi: 10.31661/jbpe.v0i0.2106-1361. PubMed PMID: 34458188. PubMed PMCID: PMC8385222.
  22. Bevelacqua JJ, Mortazavi SA, Welsh JS, Mortazavi SMJ. How Reactivation of SARS-CoV-2 in Astronauts with Dysregulated Immune Systems Can Negatively Affect the Odds of Success in Future Space Missions. J Biomed Phys Eng. 2023;13(3):297-8. doi: 10.31661/jbpe.v0i0.2104-1321. PubMed PMID: 37312889. PubMed PMCID: PMC10258206.
  23. Karimpour M, Haghani M, Bevelacqua JJ, Welsh JS, Mortazavi SA, Mortazavi SMJ, Ghadimi-Moghadam A. The Paradoxical Role of far-Ultraviolet C (far-UVC) in Inactivation of SARS-CoV-2: The Issue of Droplet Size. J Biomed Phys Eng. 2022;12(5):535-8. doi: 10.31661/jbpe.v0i0.2204-1482. PubMed PMID: 36313407. PubMed PMCID: PMC9589074.
  24. Little MP, Zhang W, Van Dusen R, Hamada N. Pneumonia After Bacterial or Viral Infection Preceded or Followed by Radiation Exposure: A Reanalysis of Older Radiobiologic Data and Implications for Low-Dose Radiation Therapy for Coronavirus Disease 2019 Pneumonia. Int J Radiat Oncol Biol Phys. 2021;109(4):849-58. doi: 10.1016/j.ijrobp.2020.09.052. PubMed PMID: 33011212. PubMed PMCID: PMC7527825.
  25. Chrysostomou AC, Vrancken B, Haralambous C, Alexandrou M, Aristokleous A, Christodoulou C, et al. Genomic Epidemiology of the SARS-CoV-2 Epidemic in Cyprus from November 2020 to October 2021: The Passage of Waves of Alpha and Delta Variants of Concern. Viruses. 2022;15(1):108. doi: 10.3390/v15010108. PubMed PMID: 36680148. PubMed PMCID: PMC9862594.
  26. Hussien SM. The immunomodulatory properties of low-level ionizing radiation as a potential treatment for COVID-19’s life-threatening symptoms. Eur J Med Res. 2023;28(1):73. doi: 10.1186/s40001-023-00999-7. PubMed PMID: 36774511. PubMed PMCID: PMC9918814.
  27. Chalkia M, Arkoudis NA, Maragkoudakis E, Rallis S, Tremi I, Georgakilas AG, et al. The Role of Ionizing Radiation for Diagnosis and Treatment against COVID-19: Evidence and Considerations. 2022;11(3):467. doi: 10.3390/cells11030467. PubMed PMID: 35159277. PubMed PMCID: PMC8834503.
  28. Little MP, Zhang W, Van Dusen R, Hamada N, Bugden M, Cao M, et al. Low-dose radiotherapy for COVID-19 pneumonia and cancer: summary of a recent symposium and future perspectives. Int J Radiat Biol. 2023;99(2):357-71. doi: 10.1080/09553002.2022.2074165. PubMed PMID: 35511152.
  29. Wen K, Bai C, Zhao H, Zhou P, Gao S, Guan H, Song M. Low dose radiation therapy attenuates ACE2 depression and inflammatory cytokines induction by COVID-19 viral spike protein in human bronchial epithelial cells. Int J Radiat Biol. 2022;98(10):1532-41. doi: 10.1080/09553002.2022.2055806. PubMed PMID: 35319335.
  30. Oksengendler BL, Ashirmetov AK, Turaeva NN, Nikiforova NN, Suleymanov SX, Zatsepin AF, Iskandarova FA. The features of Auger destruction in quasi-one-dimensional objects of inorganic and organic nature. Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms. 2022;512:66-75. doi: 10.1016/j.nimb.2021.12.009.
  31. Rödel F, Arenas M, Ott OJ, Fournier C, Georgakilas AG, Tapio S, Trott KR, Gaipl US. Low-dose radiation therapy for COVID-19 pneumopathy: what is the evidence? Strahlenther Onkol. 2020;196(8):679-82. doi: 10.1007/s00066-020-01635-7. PubMed PMID: 32388805. PubMed PMCID: PMC7211051.
  32. Nestle U, Krause M. Radiotherapy and COVID-19-everything under control or just the start of a long story? Strahlenther Onkol. 2020;196(12):1065-7. doi: 10.1007/s00066-020-01704-x. PubMed PMID: 33231738. PubMed PMCID: PMC7684561.
  33. Sharma DN, Guleria R, Wig N, Mohan A, Rath G, Subramani V, et al. Low-dose radiation therapy for COVID-19 pneumonia: a pilot study. Br J Radiol. 2021;94(1126):20210187. doi: 10.1259/bjr.20210187. PubMed PMID: 34545760. PubMed PMCID: PMC9328067.
  34. Dilucca M, Forcelloni S, Georgakilas AG, Giansanti A, Pavlopoulou A. Codon Usage and Phenotypic Divergences of SARS-CoV-2 Genes. Viruses. 2020;12(5):498. doi: 10.3390/v12050498. PubMed PMID: 32366025. PubMed PMCID: PMC7290700.
  35. Yu J, Azzam EI, Jadhav AB, Wang Y. COVID-19: The Disease, the Immunological Challenges, the Treatment with Pharmaceuticals and Low-Dose Ionizing Radiation. Cells. 2021;10(9):2212. doi: 10.3390/cells10092212. PubMed PMID: 34571861. PubMed PMCID: PMC8470324.
  36. Chrysostomou AC, Vrancken B, Koumbaris G, Themistokleous G, Aristokleous A, Masia C, et al. A Comprehensive Molecular Epidemiological Analysis of SARS-CoV-2 Infection in Cyprus from April 2020 to January 2021: Evidence of a Highly Polyphyletic and Evolving Epidemic. Viruses. 2021;13(6):1098. doi: 10.3390/v13061098. PubMed PMID: 34207490. PubMed PMCID: PMC8227210.
  37. Gao R, Zu W, Liu Y, Li J, Li Z, Wen Y, et al. Quasispecies of SARS-CoV-2 revealed by single nucleotide polymorphisms (SNPs) analysis. 2021;12(1):1209-26. doi: 10.1080/21505594.2021.1911477. PubMed PMID: 34030593. PubMed PMCID: PMC8158041.
  38. Mahallawi WH, Aljeraisi TM. In vitro cell culture model of human nasal-associated lymphoid tissue (NALT) to evaluate the humoral immune response to SARS-CoV-2 spike proteins. Saudi J Biol Sci. 2021;28(8):4516-21. doi: 10.1016/j.sjbs.2021.04.051. PubMed PMID: 33942008. PubMed PMCID: PMC8064899.
  39. Dunlap NE, Van Berkel V, Cai L. COVID-19 and low-dose radiation therapy. Radiat Med Prot. 2021;2(4):139-45. doi: 10.1016/j.radmp.2021.09.004. PubMed PMID: 34522905. PubMed PMCID: PMC8429076.
  40. Jahani Sherafat S, Mokmeli S, Rostami-Nejad M, Razaghi Z, Rezaei Tavirani M, Razzaghi M. The Effectiveness of Photobiomudulation Therapy (PBMT) in COVID-19 Infection. J Lasers Med Sci. 2020;11(Suppl 1):S23-9. doi: 10.34172/jlms.2020.S4. PubMed PMID: 33995965. PubMed PMCID: PMC7956025.
  41. Sharma L, Sharma A, Nandy SK, Kumar AP, Singh S, Chellappan DK, et al. Radiotherapy in covid-19: A review. 2021:277-85.
  42. Abdelwahed HY. Is it possible to use radiotherapy to kill intrapulmonary COVID 19 to stop its destroying effect on the lungs? Journal of MAR Case Reports. 2022;4(1):1-7.